Cargando…

Reduced Risk of Plasmodium vivax Malaria in Papua New Guinean Children with Southeast Asian Ovalocytosis in Two Cohorts and a Case-Control Study

BACKGROUND: The erythrocyte polymorphism, Southeast Asian ovalocytosis (SAO) (which results from a 27-base pair deletion in the erythrocyte band 3 gene, SLC4A1Δ27) protects against cerebral malaria caused by Plasmodium falciparum; however, it is unknown whether this polymorphism also protects agains...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosanas-Urgell, Anna, Lin, Enmoore, Manning, Laurens, Rarau, Patricia, Laman, Moses, Senn, Nicolas, Grimberg, Brian T., Tavul, Livingstone, Stanisic, Danielle I., Robinson, Leanne J., Aponte, John J., Dabod, Elijah, Reeder, John C., Siba, Peter, Zimmerman, Peter A., Davis, Timothy M. E., King, Christopher L., Michon, Pascal, Mueller, Ivo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3433408/
https://www.ncbi.nlm.nih.gov/pubmed/22973182
http://dx.doi.org/10.1371/journal.pmed.1001305
_version_ 1782242314075242496
author Rosanas-Urgell, Anna
Lin, Enmoore
Manning, Laurens
Rarau, Patricia
Laman, Moses
Senn, Nicolas
Grimberg, Brian T.
Tavul, Livingstone
Stanisic, Danielle I.
Robinson, Leanne J.
Aponte, John J.
Dabod, Elijah
Reeder, John C.
Siba, Peter
Zimmerman, Peter A.
Davis, Timothy M. E.
King, Christopher L.
Michon, Pascal
Mueller, Ivo
author_facet Rosanas-Urgell, Anna
Lin, Enmoore
Manning, Laurens
Rarau, Patricia
Laman, Moses
Senn, Nicolas
Grimberg, Brian T.
Tavul, Livingstone
Stanisic, Danielle I.
Robinson, Leanne J.
Aponte, John J.
Dabod, Elijah
Reeder, John C.
Siba, Peter
Zimmerman, Peter A.
Davis, Timothy M. E.
King, Christopher L.
Michon, Pascal
Mueller, Ivo
author_sort Rosanas-Urgell, Anna
collection PubMed
description BACKGROUND: The erythrocyte polymorphism, Southeast Asian ovalocytosis (SAO) (which results from a 27-base pair deletion in the erythrocyte band 3 gene, SLC4A1Δ27) protects against cerebral malaria caused by Plasmodium falciparum; however, it is unknown whether this polymorphism also protects against P. vivax infection and disease. METHODS AND FINDINGS: The association between SAO and P. vivax infection was examined through genotyping of 1,975 children enrolled in three independent epidemiological studies conducted in the Madang area of Papua New Guinea. SAO was associated with a statistically significant 46% reduction in the incidence of clinical P. vivax episodes (adjusted incidence rate ratio [IRR] = 0.54, 95% CI 0.40–0.72, p<0.0001) in a cohort of infants aged 3–21 months and a significant 52% reduction in P. vivax (blood-stage) reinfection diagnosed by PCR (95% CI 22–71, p = 0.003) and 55% by light microscopy (95% CI 13–77, p = 0.014), respectively, in a cohort of children aged 5–14 years. SAO was also associated with a reduction in risk of P. vivax parasitaemia in children 3–21 months (1,111/µl versus 636/µl, p = 0.011) and prevalence of P. vivax infections in children 15–21 months (odds ratio [OR] = 0.39, 95% CI 0.23–0.67, p = 0.001). In a case-control study of children aged 0.5–10 years, no child with SAO was found among 27 cases with severe P. vivax or mixed P. falciparum/P. vivax malaria (OR = 0, 95% CI 0–1.56, p = 0.11). SAO was associated with protection against severe P. falciparum malaria (OR = 0.38, 95% CI 0.15–0.87, p = 0.014) but no effect was seen on either the risk of acquiring blood-stage infections or uncomplicated episodes with P. falciparum. Although Duffy antigen receptor expression and function were not affected on SAO erythrocytes compared to non-SAO children, high level (>90% binding inhibition) P. vivax Duffy binding protein–specific binding inhibitory antibodies were observed significantly more often in sera from SAO than non-SAO children (SAO, 22.2%; non-SAO, 6.7%; p = 0.008). CONCLUSIONS: In three independent studies, we observed strong associations between SAO and protection against P. vivax malaria by a mechanism that is independent of the Duffy antigen. P. vivax malaria may have contributed to shaping the unique host genetic adaptations to malaria in Asian and Oceanic populations. Please see later in the article for the Editors' Summary.
format Online
Article
Text
id pubmed-3433408
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-34334082012-09-12 Reduced Risk of Plasmodium vivax Malaria in Papua New Guinean Children with Southeast Asian Ovalocytosis in Two Cohorts and a Case-Control Study Rosanas-Urgell, Anna Lin, Enmoore Manning, Laurens Rarau, Patricia Laman, Moses Senn, Nicolas Grimberg, Brian T. Tavul, Livingstone Stanisic, Danielle I. Robinson, Leanne J. Aponte, John J. Dabod, Elijah Reeder, John C. Siba, Peter Zimmerman, Peter A. Davis, Timothy M. E. King, Christopher L. Michon, Pascal Mueller, Ivo PLoS Med Research Article BACKGROUND: The erythrocyte polymorphism, Southeast Asian ovalocytosis (SAO) (which results from a 27-base pair deletion in the erythrocyte band 3 gene, SLC4A1Δ27) protects against cerebral malaria caused by Plasmodium falciparum; however, it is unknown whether this polymorphism also protects against P. vivax infection and disease. METHODS AND FINDINGS: The association between SAO and P. vivax infection was examined through genotyping of 1,975 children enrolled in three independent epidemiological studies conducted in the Madang area of Papua New Guinea. SAO was associated with a statistically significant 46% reduction in the incidence of clinical P. vivax episodes (adjusted incidence rate ratio [IRR] = 0.54, 95% CI 0.40–0.72, p<0.0001) in a cohort of infants aged 3–21 months and a significant 52% reduction in P. vivax (blood-stage) reinfection diagnosed by PCR (95% CI 22–71, p = 0.003) and 55% by light microscopy (95% CI 13–77, p = 0.014), respectively, in a cohort of children aged 5–14 years. SAO was also associated with a reduction in risk of P. vivax parasitaemia in children 3–21 months (1,111/µl versus 636/µl, p = 0.011) and prevalence of P. vivax infections in children 15–21 months (odds ratio [OR] = 0.39, 95% CI 0.23–0.67, p = 0.001). In a case-control study of children aged 0.5–10 years, no child with SAO was found among 27 cases with severe P. vivax or mixed P. falciparum/P. vivax malaria (OR = 0, 95% CI 0–1.56, p = 0.11). SAO was associated with protection against severe P. falciparum malaria (OR = 0.38, 95% CI 0.15–0.87, p = 0.014) but no effect was seen on either the risk of acquiring blood-stage infections or uncomplicated episodes with P. falciparum. Although Duffy antigen receptor expression and function were not affected on SAO erythrocytes compared to non-SAO children, high level (>90% binding inhibition) P. vivax Duffy binding protein–specific binding inhibitory antibodies were observed significantly more often in sera from SAO than non-SAO children (SAO, 22.2%; non-SAO, 6.7%; p = 0.008). CONCLUSIONS: In three independent studies, we observed strong associations between SAO and protection against P. vivax malaria by a mechanism that is independent of the Duffy antigen. P. vivax malaria may have contributed to shaping the unique host genetic adaptations to malaria in Asian and Oceanic populations. Please see later in the article for the Editors' Summary. Public Library of Science 2012-09-04 /pmc/articles/PMC3433408/ /pubmed/22973182 http://dx.doi.org/10.1371/journal.pmed.1001305 Text en © 2012 Rosanas-Urgell et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Rosanas-Urgell, Anna
Lin, Enmoore
Manning, Laurens
Rarau, Patricia
Laman, Moses
Senn, Nicolas
Grimberg, Brian T.
Tavul, Livingstone
Stanisic, Danielle I.
Robinson, Leanne J.
Aponte, John J.
Dabod, Elijah
Reeder, John C.
Siba, Peter
Zimmerman, Peter A.
Davis, Timothy M. E.
King, Christopher L.
Michon, Pascal
Mueller, Ivo
Reduced Risk of Plasmodium vivax Malaria in Papua New Guinean Children with Southeast Asian Ovalocytosis in Two Cohorts and a Case-Control Study
title Reduced Risk of Plasmodium vivax Malaria in Papua New Guinean Children with Southeast Asian Ovalocytosis in Two Cohorts and a Case-Control Study
title_full Reduced Risk of Plasmodium vivax Malaria in Papua New Guinean Children with Southeast Asian Ovalocytosis in Two Cohorts and a Case-Control Study
title_fullStr Reduced Risk of Plasmodium vivax Malaria in Papua New Guinean Children with Southeast Asian Ovalocytosis in Two Cohorts and a Case-Control Study
title_full_unstemmed Reduced Risk of Plasmodium vivax Malaria in Papua New Guinean Children with Southeast Asian Ovalocytosis in Two Cohorts and a Case-Control Study
title_short Reduced Risk of Plasmodium vivax Malaria in Papua New Guinean Children with Southeast Asian Ovalocytosis in Two Cohorts and a Case-Control Study
title_sort reduced risk of plasmodium vivax malaria in papua new guinean children with southeast asian ovalocytosis in two cohorts and a case-control study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3433408/
https://www.ncbi.nlm.nih.gov/pubmed/22973182
http://dx.doi.org/10.1371/journal.pmed.1001305
work_keys_str_mv AT rosanasurgellanna reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy
AT linenmoore reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy
AT manninglaurens reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy
AT raraupatricia reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy
AT lamanmoses reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy
AT sennnicolas reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy
AT grimbergbriant reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy
AT tavullivingstone reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy
AT stanisicdaniellei reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy
AT robinsonleannej reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy
AT apontejohnj reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy
AT dabodelijah reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy
AT reederjohnc reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy
AT sibapeter reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy
AT zimmermanpetera reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy
AT davistimothyme reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy
AT kingchristopherl reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy
AT michonpascal reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy
AT muellerivo reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy